Jian Fei

Chiral Quest (Suzhou) Co. Ltd. provides drug discovery services. It focuses on the development and manufacture of chiral catalysts, development of synthetic processes, and a technology applications platform. Its products include a, b, and Cyclicb-amino acids; b-hydroxy acids; chiral amines, alcohols, amino alcohols, and pyrrolidines; succinates; and achiral compounds, a-hydroxy acids, and APIs and intermediates. Chiral Quest has one manufacturing site in Jiangxi province, and three overseas offices in USA, Europe & India respectively. The company was founded by Xumu Zhang in 2000 and is headquartered in Suzhou, China.

Shenzhen Investment Holdings Co., Ltd. operates as a state-owned asset management company. Its business activities include management of properties, capital operation, investment and financing, transportation logistics, manufacturing and trading, and modern service industries. The company was founded on October 13, 2004 and is headquartered in Shenzhen, China.

Shanghai LinBell Electronic Technologies Co., Ltd. designs and manufactures large screen display system. Its products include super narrow liquid crystal display unit and maintenance, widescreen LCD multi screen system, LCD advertising screen and super narrow plasma display unit. The company was founded on September 5, 2007 and is headquartered in Shanghai, China.

Shanghai SinoMCU Microelectronics Co., Ltd. engages in the development and sale of microcontroller units (MCU). Its products include 8-bit one-time, general purpose input/output, infrared remote control, touch button, universal analog to digital converters, dedicated application-specific integrated circuits, RF control, 8-bit flash general purpose, internet of things control, and motor control chip. The company was founded by Jian Lu on November 26, 2010 and is headquartered in Shanghai, China.

Shandong Bestcomm Pharmaceutical Co., Ltd. is engaged in the research, development and production of domestic pharmaceutical technology. It also offers the development of various new drugs. The company was founded on August 2, 2000 and is headquartered in Jinan, China.

Hangzhou Sciwind Biosciences Co., Ltd. is a biopharmaceutical company based in Hangzhou, China. The Chinese company's product pipeline includes potentially first-in-class and drug candidates, such as the long-acting glp-1 peptide analog ecnoglutide (phase 3), oral glp-1 peptide analog xw004 (phase 1), and oral small molecule glp-1 receptor agonist xw014 (phase 1). Sciwind has developed multiple proprietary technologies, including oral peptide and inhaled protein therapeutic delivery platforms, and identified a series of drug candidates based on these core platform technologies. The company was founded in 2017 by Hai Pan, who has been the CEO since 2017.

Shanghai Bocimed Pharmaceutical Co., Ltd. engages in the research and development of new drugs for its clients. Its services include discovery, research, registration, and clinical evaluation of drugs. The company was founded by Shu Huan Ying in 2007 and is headquartered in Shanghai, China.

Wuxi Zhongding Integrated Technology Co. Ltd. engages in logistics. Its activities includes transporting, warehousing, and related IT systems and software. The company was founded on March 7, 2017 and is headquartered in Wuxi, China.

Shanghai Boendengte Technology Co., Ltd. is a company that provides high-quality and cost-effective oral products through independent innovation. The company is based in Shanghai, China and was founded in 2009 by Fang Jun Tian. The Chinese company offers a range of oral equipment and consumables, including earl imaging products, simo dental microscopy, bomei star comprehensive treatment channel, corel correction products, iezplanting series, yirui m3 pipe series, and other products. The company is also the agent of the northern and Italian laser nationwide in the vdw of Germany.

Jiangsu Shengsi Biopharmaceutical Co., Ltd. operates as a Chinese pharmaceutical company. The company is based in Nantong, China. It was founded in 2020, and the CEO is Hao Yue Hu.

Shanghai Innostar Biotechnology Co., Ltd. engages in the provision of comprehensive research and development services for biopharmaceutical non-clinical research. Its services include early-stage drug discovery, clinical testing & translational research, non-clinical safety evaluation, non-clinical pharmacokinetic studies, and non-clinical pharmacodynamic studies. The company was founded on May 12, 2010 and is headquartered in Shanghai, China.